Watch CTOR. Know when insiders buy.
One email the day a filing lands. Free.
CTOR
CITIUS ONCOLOGY, INC.
0.91
−0.03 −3.19%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
21
FLAG · shorts 21
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $84.6MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$46.1MNET CASH —52W 0.49 – 2.03SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Jun 30 | $1.5M | — | 67.1% | −$8.7M | −$8.9M | — | -0.08 | −$2.7M | — | — | Aug 14 |
| Q2 2026 · Mar 31 | $1.7M | — | 80.3% | −$28.6M | −$26.6M | — | -0.27 | −$3.8M | — | — | Aug 14 |
| Q1 2026 · Dec 31 | $3.9M | — | 80.0% | −$5.3M | −$5.5M | — | -0.06 | −$7.4M | — | — | Aug 14 |
| Q4 2025 · Sep 30derived | — | — | — | −$4.7M | −$5M | — | -0.06 | — | — | — | Dec 23 |
| Q3 2025 · Jun 30 | — | — | — | −$4.9M | −$5.4M | — | -0.08 | — | — | — | Aug 14 |
| Q2 2025 · Mar 31 | — | — | — | −$7.5M | −$7.7M | — | -0.11 | — | — | — | Aug 14 |
| Q1 2025 · Dec 31 | — | — | — | −$6.4M | −$6.7M | — | -0.09 | — | — | — | Aug 14 |
| Q4 2024 · Sep 30derived | — | — | — | −$6.7M | −$6.8M | −4413.5% | -0.10 | — | — | — | Dec 23 |
| Q3 2024 · Jun 30 | — | — | — | −$4.6M | −$4.8M | — | -0.07 | −$366K | — | — | Aug 12 |
| Q2 2024 · Mar 31 | — | — | — | −$268K | −$4.8M | — | -0.07 | −$192K | — | — | Aug 12 |
| Q1 2024 · Dec 31 | — | — | — | −$244K | −$4.7M | — | -0.07 | −$219K | — | — | Aug 12 |
| Q4 2023 · Sep 30 | — | — | — | −$421K | $158K | — | 0.02 | −$113K | — | — | Nov 20 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Sep 30 | — | — | −$23.5M | −$24.8M | — | -0.34 | −$5.5M | — | — | — | — |
| FY2024 · to Sep 30 | — | — | −$20.6M | −$21.1M | — | -0.31 | $126K | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$1M | $2.4M | — | 0.27 | −$601K | — | — | — | — |
| FY2023 · to Sep 30 | — | — | — | −$12.7M | — | -0.19 | — | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$138K | $381K | — | 0.12 | −$48K | — | — | — | — |
Every number comes from CITIUS ONCOLOGY, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.